Photo: REUTERS file
national

Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

15 Comments

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© Thomson Reuters 2020.

©2021 GPlusMedia Inc.

15 Comments
Login to comment

I hope it will work out for Japan, it appears to have a good record in other countries (according to article) . . . the other countries of the world also need a better hope.

2 ( +4 / -2 )

I have seen this news article so many times since the beginning of COVID. So far Fujifilm have been seeking approval 50 times, and considered the drug as a treatment about 100 times.

12 ( +12 / -0 )

I hope it works but I am not going to be the first one in line to try it.

0 ( +1 / -1 )

WHO reported Remdesivir not effective to COVID 19. Avigan is the same type of anti-virus medicine. Both are existing medicine for other virus infections. So far, there is no medicine discovered directly working for COVID 19. This will become a long war.

5 ( +6 / -1 )

It doesn't work.

4 ( +7 / -3 )

It doesn't work.

No, it doesn't. But it was decided a long time ago that it will be approved. Reversing a decision is a huge loss-of-face, so it almost never happens.

6 ( +7 / -1 )

Time for the CEO to have another game of golf, maybe this time with PM Suga or MHLW Tamura.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

Reported in the WSJ earlier, studies are looking at the doses required, as well as the possibility of it being used in combination with other drugs, but some have not been published due to a lack of statistical significance.

2 ( +2 / -0 )

If we don't have any knowledge, I think we should not make any comments. Fuji could not apply for a long time due to lack of many patients for clinical trials in Japan. However, I agree that Avigan is not efficient to the serious patients.

0 ( +2 / -2 )

@Thomas Goodtime

It doesn't work.

Is there a link or articles for this? (I just haven’t heard this). Not posting for argument sake but since I live here I want to read up on it a bit.

0 ( +1 / -1 )

This was all decided when Abe was in power. Should have called it Abegain

2 ( +2 / -0 )

The potential to be the new Thalidomide then.

1 ( +1 / -0 )

From reporting in India (Deccan Chronicle)...

"However, the positive results from the study should be interpreted with caution as other therapies were administered in this non-randomised, open-label study, which could have confused the results. “

So, in other words, 'success' is unsubstantiated and needs to be taken with a grain of salt, until further testing proves otherwise. Or not.

1 ( +1 / -0 )

BBC reported on it as well:

Covid: Remdesivir 'has little or no effect' on survival, says WHO

https://www.bbc.com/news/world-54566730

They got Trump to take Remdesivir (mixed in with other treatments) to create more demand for it and "say" that it is 'effective'.

https://swprs.org/facts-about-covid-19/

If you look at the details (and their sources) VS what they are presenting to you in the news you'll realize that they're trying to keep people in FEAR for a reason: Pharma product demand / sales

1 ( +1 / -0 )

No report of study of effectiveness of the drug against corona virus from external independent credible institutions. Human lifes are involved, hope nationalism is kept out of decisions regarding drugs.

2 ( +2 / -0 )

https://www.nytimes.com/2020/05/05/business/japan-avigan-coronavirus.html?campaign_id=154&emc=edit_cb_20200506&instance_id=18249&nl=coronavirus-briefing&regi_id=49359514&segment_id=26680&te=1&user_id=9c748ac6c3d1ed95a04f0beb1d0eb89b

The New York Times ran an article saying that Avigan is worse than useless; it actually causes harm.

3 ( +3 / -0 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites